No profile data available.
Evaxion A/S (EVAX) is a healthcare company in the antibacterial pharmaceuticals industry, based in Horsholm, Denmark, with about 46 full-time employees.
It reported revenue of $7.53 million for fiscal year 2025, up 125.1% from fiscal year 2024, and net income of -$7.71 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $27.70 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
Evaxion A/S reported $7.53 million in revenue for fiscal year 2025, up 125.1% from $3.34 million in fiscal year 2024. In Q2 2026 revenue was $0.
$27.70 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include PolyPid Ltd. (PYPD), Spero Therapeutics, Inc. (SPRO), China Pharma Holdings, Inc. (CPHI), Seres Therapeutics, Inc. (MCRB).